A detailed history of Principal Securities, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 569 shares of NTLA stock, worth $8,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
569
Previous 87 554.02%
Holding current value
$8,136
Previous $1.95 Million 500.56%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$19.72 - $27.36 $9,505 - $13,187
482 Added 554.02%
569 $11.7 Million
Q2 2024

Jul 31, 2024

SELL
$20.02 - $27.22 $500 - $680
-25 Reduced 22.32%
87 $1.95 Million
Q1 2024

May 10, 2024

BUY
$23.82 - $32.8 $571 - $787
24 Added 27.27%
112 $3.08 Million
Q4 2023

Feb 07, 2024

BUY
$23.16 - $32.34 $2,038 - $2,845
88 New
88 $2.68 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.